Products Recommend
Plasma filter (OP-03,OP-05,OP-08)
Double plasma filter (EC-20,30,40,50)
Dialysis System MDS-101
Location:Home >> ProductsProducts




Neurological diseases(e.g., Myasthenia gravis, Guillain-Barré syndrome, Chronic inflammatory demyelinating polyneuropathy, Multiple sclerosis)

Features of IMMUSORBA TR-350 (L)

  • Therapeutic plasmapheresis by removing pathogenic substances (anti-acetylcholine receptor antibodies and immune complexes) from patient's plasma by selective adsorption.
  • No need for the replacement of plasma, minimizing the risk of infection with hepatitis, AIDS, etc.
  • Applicable to patients with protein allergy.


Plasma samples were collected at the inlet and outlet of the column when 1L plasma was treated.

*AChR: Acetylcholine receptor
Shibuya et al. [Article in Japanese] Chiryo 66 : 49-55, 1984

Blood samples for removal rate were collected before and after treatment.
Treated plasma volume: 2L

Shibuya et al. Current Practice in Therapeutic Plasmapheresis 166-172, 1985

Clinical course

Mean values of myasthenia gravis score and titer of AChR antibodies in the 11 improved patients after immunoadsorption therapy. Consecutive immunoadsorption treatments induced a significant fall of the myasthenia gravis score and a decrease in the titer of AChR antibodies. The myasthenia gravis score remained low even on day 42 despite the rise in AChR antibody titers.

Shibuya et al. J Neurol Neurosurg Psychiatry 57: 578-581, 1994

Sixty-three Guillain-Barré Syndrome (GBS) patients were enrolled. These patients were treated with plasma adsorption (PA, n=39: Immusorba TR-350), plasma exchange (PE, n=14), or immunoglobulin treatment (IVIg, n=10). The number of days required for one or two functional grades improvement was 20.3 ±15.3 or 34.8 ± 20.5 days, respectively. Treatment methods (PA, PE, or IVIg) did not significantly influence the outcome. Since PA does not result in a risk of unknown infection, choosing a PA may be justified.

Seta et al. Factors influencing outcome in Guillain-Barré Syndrome: comparison of plasma adsorption against other treatments. Clin Neurol Neurosurg. 107(6): 491-496, 2005


IMMUSORBA TR-350 (L) specifications

Immunoadsorption Column

Adsorbent Material Tryptophan immobilized polyvinylalcohol gel
Volume 350 mL
Priming Volume 300 mL
Container Material Polypropylene
Dimension 211mm[L] x 62mm[D]
Weight 650g
Sterilization High pressure steam

Particle Removal Filter

Filter Material Polyethylene (coated with ethylene-vinylalcohol copolymer)
Area 0.07 m2
Container Material Poly (vinyl chloride)
Dimension 165mm[L] x 22mm[D]
Priming Volume 30 mL
Sterilization Ethylene oxide


For patients undergoing treatment with angiotensin-converting enzyme (ACE) inhibitor, there is a possibility that treatment with the IMMUSORBA TR-350 will lead to a drop in blood pressure. Simultaneous treatment with ACE inhibitor and the IMMUSORBA TR-350 must be avoided.
The IMMUSORBA TR-350 is intended for the treatment of plasma. Never run whole blood through the IMMUSORBA TR-350. Thrombocytes cannot pass through the IMMUSORBA TR-350 and may cause blockage.
Do not use IMMUSORBA TR-350 with plasma containing a large amount of thrombocytes.

Featured References

Hirata et al.
Ther Apher Dial. 7:85-90, 2003.
Yoshida et al.
IMMUSORBA TR and IMMUSORBA PH: Basics of design and features of functions.
Ther Apher. 4:127-34, 2000.


Yoshida et al.
IMMUSORBA TR and IMMUSORBA PH: Basics of design and features of functions.
Ther Apher. 4:127-34, 2000.
Haupt et al.
Apheresis and selective adsorption plus immunoglobulin treatment in Guillain-Barré syndrome.
Ther Apher. 4:198-200, 2000.
Ota et al.
Neutrophil activation in immunoadsorption.
Ther Apher. 4:229-34, 2000.
Yang et al.
Plasma adsorption in critical care.
Ther Apher. 6:184-8, 2002.
Hirata et al.
Ther Apher Dial. 7:85-90, 2003.
Beige et al.
Immunoadsorption with tryptophan adsorbers for successful treatment of late steroid-refractory recurrent focal glomerulosclerosis.
Am J Transplant. 3:1459, 2003.
Splendiani et al.
Plasmaperfusion on triptophan columns can improve the clinical outcome of patients affected with myasthenia gravis.
Artif Cells Blood Substit Immobil Biotechnol. 31:69-79, 2003.
Luftl et al.
Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber.
Br J Dermatol. 149:598-605, 2003.
Okamiya et al.
Tryptophan-immobilized column-based immunoadsorption as the choice method for plasmapheresis in Guillain-Barre syndrome.
Ther Apher Dial. 8:248-53, 2004.
Seta et al.
Factors influencing outcome in Guillain-Barré Syndrome: comparison of plasma adsorption against other treatments.
Clin Neurol Neurosurg. 107:491-6, 2005.
Arakawa et al.
Immunoadsorption therapy for a child with Guillain-Barré syndrome subsequent to Mycoplasma infection: a case study.
Brain Dev. 27:431-3, 2005.
Wagner et al.
[Long-term treatment of refractory myasthenia gravis with immunoadsorption].
Dtsch Med Wochenschr. 133:2377-82, 2008. German
Wenning et al.
Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.
N Engl J Med. 361:1075-80, 2009.
Galldiks et al.
Immunoadsorption in patients with chronic inflammatory demyelinating polyradiculoneuropathy with unsatisfactory response to first-line treatment.
Eur Neurol. 66:183-9, 2011.
Nagatomo et al.
Specific immunoadsorption therapy using a tryptophan column in patients with refractory heart failure due to dilated cardiomyopathy.
J Clin Apher. 26:1-8, 2011.
Nagane et al.
Early aggressive treatment strategy against myasthenia gravis.
Eur Neurol. 65:16-22, 2011.
Köhler et al.
A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis.
J Clin Apher. 26:347-55, 2011.
Trebst et al.
Immunoadsorption therapy for steroid-unresponsive relapses in patients with multiple sclerosis.
Blood Purif. 33:1-6, 2012.
Koziolek et al.
Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis.
J Neuroinflammation. 26;9:80, 2012.
Koziolek et al.
Immunoadsorption in steroid-refractory multiple sclerosis.
Atheroscler Suppl. 14:175-8, 2013.
Klingel et al.
Neurologic diseases of the central nervous system with pathophysiologically relevant autoantibodies--perspectives for immunoadsorption.
Atheroscler Suppl. 14:161-5, 2013.
Heigl et al.
Immunoadsorption in steroid-refractory multiple sclerosis: clinical experience in 60 patients.
Atheroscler Suppl. 14:167-73, 2013.
Yonee et al.
Association of acute cerebellar ataxia and human papilloma virus vaccination: a case report.
Neuropediatrics. 44:265-7, 2013.